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Abstract
Background: Leishmania is a mammalian parasite affecting over 12 million individuals worldwide. Current treatments are
expensive, cause severe side effects, and emerging drug resistance has been reported. Vaccination is the most cost-effective
means to control infectious disease but currently there is no vaccine available against Leishmaniasis. Lactococcus lactis is a
non-pathogenic, non-colonizing Gram-positive lactic acid bacterium commonly used in the dairy industry. Recently, L. lactis
was used to express biologically active molecules including vaccine antigens and cytokines.
Methodology/Principal findings: We report the generation of L. lactis strains expressing the protective Leishmania antigen,
LACK, in the cytoplasm, secreted or anchored to the bacterial cell wall. L. lactis was also engineered to secrete biologically
active single chain mouse IL-12. Subcutaneous immunization with live L. lactis expressing LACK anchored to the cell wall
and L. lactis secreting IL-12 significantly delayed footpad swelling in Leishmania major infected BALB/c mice. The delay in
footpad swelling correlated with a significant reduction of parasite burden in immunized animals compared to control
groups. Immunization with these two L. lactis strains induced antigen-specific multifunctional TH1 CD4
+ and CD8
+ T cells
and a systemic LACK-specific TH1 immune response. Further, protection in immunized animals correlated with a Leishmania-
specific TH1 immune response post-challenge. L. lactis secreting mouse IL-12 was essential for directing immune responses
to LACK towards a protective TH1 response.
Conclusions/Significance: This report demonstrates the use of L. lactis as a live vaccine against L. major infection in BALB/c
mice. The strains generated in this study provide the basis for the development of an inexpensive and safe vaccine against
the human parasite Leishmania.
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Introduction
Leishmaniasis, caused by the protozoan parasites of the genus
Leishmania, affects over 12 million individuals worldwide, 1.5–2.0
million of whom develop symptomatic disease every year [1]. The
parasite is spread by the sand fly vector and causes a spectrum of
diseases depending on the parasite species and the host immune status.
Clinical manifestations of the human disease range from self-limiting
cutaneous leishmaniasis, disfiguring mucocutaneous leishmaniasis, to
fatal visceral leishmaniasis. Current treatments use toxic pentavalent
antimonial compounds. These treatments are laborious and expen-
sive, cause severe side effects and emerging drug resistance has been
reported [2]. Therefore, an effective Leishmania vaccine would be
desirable. Leishmanisation using live Leishmania major parasites
generates long-lasting protective immunity against further infection,
indicating that the development of a Leishmania v a c c i n ei sf e a s i b l e[ 1 ] .
Immunity against L. major infection is well characterized in the
mouse model and depends mainly on TH1 immune responses
mediated by CD4
+ T cells induced by the essential cytokine IL-12
[3,4]. However, a role for CD8
+ T and NK cells has been
described in acquired resistance against Leishmania [5,6]. Several
protective antigens against L. major have been characterized and
protection has been reported in animal models after immunization
with antigen-encoding DNA vectors or recombinant proteins
formulated with TH1-inducing adjuvants, such as IL-12 or TLR
ligands [7]. One of the best-studied L. major antigens is the
Leishmania homologue of activated C kinase (LACK). It was first
identified as a T cell epitope from soluble Leishmania antigens (SLA)
that conferred protection against L. major challenge [8]. This
antigen has since been found to be highly conserved among
Leishmania strains, although its function is not clear. It was
demonstrated that LACK is crucial for the viability of the parasite
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30945as well as for host infection and parasite reproduction in infected
macrophages [9]. Furthermore, it was suggested that LACK plays
a role in DNA replication and RNA synthesis [10]. LACK has
been shown to be protective against L. major challenge in mice as a
recombinant protein vaccine administered with recombinant IL-
12 as an adjuvant [8]. It was also shown to be effective as DNA or
recombinant Vaccinia virus vaccine in different studies [11–14].
LACK was also tested as a heterologous live bacterial vaccine.
Administration of LACK-expressing Listeria monocytogenes partially
protected mice against L. major challenge [15,16], whereas
immunization with LACK-expressing Salmonella enterica as part of
a DNA prime, live bacteria-boost strategy was found to enhance
protection against L. major challenge [17].
Lactococcus lactis is a lactic acid bacterium commonly used in the
dairy industry and is known to be non-pathogenic and non-
colonizing [18]. Accordingly, L. lactis was given Generally
Recognized As Safe (GRAS) status by the U.S. Food and Drug
Administration [19]. For over a decade, L. lactis has been used as a
live bacterial delivery vector [20]. Early studies showed that
genetically modified L. lactis heterologously expressing fragment C
of the tetanus toxin (TTFC) was able to elicit antigen-specific
immune responses and protect against disease [21–23]. Since then,
many studies have demonstrated the use of L. lactis to express and
deliver antigens and biologically active molecules such as cytokines
[24,25]. In 2006, L. lactis expressing human IL-10 was used in a
Phase I trial to treat patients with Crohn’s disease [26]. The
authors demonstrated that high consecutive daily doses of L. lactis
administered orally were well-tolerated. Recently, a Phase II
clinical trial using strains of L. lactis secreting human IL-10 was
completed and other pre-clinical trials are being prepared using
L. lactis to treat various diseases [27].
We have previously demonstrated that L. lactis elicits an innate
inflammatory response and has the ability to modulate DC
maturation, which indicates a capacity for adjuvanticity [28]. In
addition, we showed that L. lactis-based vaccines expressing the
A2 antigen from Leishmania donovani are a feasible approach in the
generation of live vaccines against visceral leishmaniasis in mice
[29]. In this study, we generated strains of L. lactis expressing the
LACK antigen of Leishmania at different subcellular localizations
(in the cytoplasm, secreted, or anchored to the cell-wall). We also
generated a strain of L. lactis secreting mouse single chain IL-12.
IL-12 is a potent heterodimeric cytokine that induces TH1 cells,
enhances CTL maturation, promotes NK cell activity and
induces IFN-c production [30]. Furthermore, IL-12 possesses
adjuvant properties and plays an essential role in immunity
against L. major [3]. We demonstrate that subcutaneous
immunization with L. lactis displaying the LACK antigen on
the cell surface in combination with L. lactis secreting mouse
single-chain IL-12 was able to elicit antigen-specific humoral and
cellular immune responses and reduced parasite burden in L.
major infected BALB/c mice.
Materials and Methods
Bacterial strains and growth conditions
Escherichia coli strain DH5a was used for DNA cloning. E. coli
strain BL21 (DE3) was used for expression and purification of
His-LACK. E. coli strains were grown with shaking in LB broth
(Wisent; St. Bruno, QC, Canada) at 37uC. L. lactis subsp. cremoris
strain NZ9000 was grown without shaking in M17 medium
(Oxoid; Basingstoke, UK) supplemented with 0.5% glucose
(GM17) or, where indicated, in three times the manufacturer’s
recommended concentration of M17 supplemented with glucose
(G3xM17) at 30uC. The NZ9000 strain is a plasmid free
derivative of the dairy starter strain NCDO71 that is sui-
table for use as a live vaccine vector [31]. Antibiotics were
added at the following concentrations: ampicillin (Amp) 100 mg/
ml; spectinomycin (Spec) 300 mg/ml; chloramphenicol (Cam)
10 mg/ml.
Plasmids
The pDL278 (pDL) E. coli-L. lactis shuttle plasmid containing a
nisin-inducible promoter (PnisA) was used for antigen expression as
previously described [29]. The LACK gene was PCR amplified
from L. donovani 1S-2D genomic DNA (NsiI). The LACK gene was
cloned downstream of the PnisA promoter (NsiI) to direct protein
expression in the cytoplasm of L. lactis (pDL-PnisA-cytoLACK).
DNA sequencing confirmed that the cloned gene matches the
sequence of LACK from L. donovani [32] and L. major [8]. As
previously described, the Usp45 secretion signal was PCR
amplified from pCWA:E7 (kindly provided by Dr. Langella)
[33,34] and cloned between the promoter and the LACK gene of
the cytoplasmic construct (NsiI) to direct protein expression to the
culture medium (pDL-PnisA-secLACK). To add the cell-wall
anchoring (cwa) domain, a restriction site was first introduced at
the 39-end of the LACK gene. A fragment including the PnisA
promoter, the secretion signal and the LACK gene was PCR
amplified to add a NheI site before the stop codon and was cloned
into pDL. The cwa domain was PCR amplified from pCWA:E7
and was cloned downstream of the LACK gene (NheI). The
secretion signal (N-terminus) and the cwa domain (C-terminus)
directs the LACK protein to be anchored to the cell-wall (pDL-
PnisA-cwaLACK).
To create a N-terminal His-tagged version of LACK for
protein purification from E. coli, the LACK gene was PCR
amplified from L. donovani 1S-2D genomic DNA (NdeI/BamHI)
and cloned into pET-16b (Novagene; Darmstadt, Germany)
(NdeI/BamHI).
To generate a L. lactis strain secreting mouse IL-12, a codon
optimized version of the single chain mouse IL-12 gene [35] was
engineered (NsiI/NheI) (scIL-12opt, GenScript; Piscataway, NJ).
The optimized gene was introduced into pBluescript II SK- (pBS)
(SalI/XbaI). The nisin-inducible promoter (PnisA) was PCR
amplified from the pSEC-scIL-12 template kindly provided by
Dr. Bermu ´dez-Humara ´n [35] and was cloned directly upstream of
scIL-12opt (SalI/NsiI). The secretion signal was PCR amplified
from pCWA:E7 and then introduced between the promoter and
the gene (NsiI). The expression cassette was excised from pBS
(SalI/BamHI) and introduced into the E. coli-L. lactis shuttle
plasmid pLE1 (pLE1-PnisA-secIL-12) [36]. To create a N-
terminal His-tagged version of scIL-12opt for protein purification
from E. coli, the optimized scIL-12 gene was excised from pLE1-
PnisA-secIL-12 (NsiI), blunted with T4 DNA Polymerase, and
digested with BamHI. The fragment was cloned into pET-16b
(Novagene), which had been previously digested with XhoI,
blunted, and then digested with BamHI. All plasmid constructs
were confirmed by DNA sequencing. Primers used for PCR
amplifications are shown in Table 1.
Protein expression and Western blotting
Saturated overnight cultures of L. lactis were diluted (,1/20) in
fresh media with antibiotics and grown until OD600=0.4–0.5.
Protein expression was induced with the addition of nisin to a final
concentration of 10 ng/ml and bacteria were grown for an
additional 3 hours. 20 ml of bacterial culture was centrifuged at
4,3006g for 10 min at 4uC; the supernatant was directly used for
Western blotting and the cell pellet was used for total cell protein
extraction. Bacterial cells were resuspended in 100 ml TES-LMR
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sucrose, 1 mg/ml lysozyme, 50 U/ml mutanolysin, and 0.1 mg/
ml RNaseA) and incubated at 37uC for 1 hour. The cells were
lysed by the addition of 100 mlo fT E +4% SDS and then incubated
in boiling water for 5 min. Protein preparations were resolved on
12% SDS-PAGE and transferred onto PVDF membrane
(Immobilon-P, Millipore; Billerica, MA) for Western blotting.
Membranes were blotted with polyclonal anti-LACK antibodies
kindly provided by Dr. Antoine [37], diluted 1:30,000 in PBS-1%
Tween-20 (PBS-T, Fisher; Ottawa, ON) containing 5% non-fat
dried milk. Anti-rabbit antibodies conjugated to horse radish
peroxidase (HRP, Sigma-Aldrich, Oakville, ON) were used as
the secondary antibody at a dilution of 1:10,000 in PBS-T+5%
milk. To confirm the localization of LACK expressed from
different plasmid constructs in L. lactis, a whole cell ELISA
protocol was employed as previously described [29]. To detect
mouse IL-12, membranes were blotted with anti-mouse IL-12
neutralizing antibody (R&D Systems, Minneapolis, MN) 1:10,000
in PBS-T+5% milk. Anti-goat-HRP (Sigma) was used as secondary
antibody at a dilution of 1:10,000 in PBS-T+5% milk. Proteins
were detected using Immobilon Western Chemiluminescent HRP
Substrate (Millipore) and visualized using the VersaDoc Molecular
Imager (Bio-Rad; Hercules, CA) with QuantityOne software
(Bio-Rad).
To determine the levels of single chain IL-12 secreted by L.
lactis, bacteria were grown in G3xM17 and induced with nisin as
described above. Proteins in bacterial supernatant were then
concentrated using 50 k Amicon Ultra Centrifugal Filter Units
(Millipore) and the concentration of mouse IL-12p70 was
determined by ELISA (eBioscience, San Diego, CA).
His-tagged LACK was purified from E. coli as previously
described [29]. The purified LACK protein was dialysed in PBS
(3,5 MWCO, 3–12 ml, Thermo Scientific; Waltham, MA)
according to manufacturer’s protocol before usage in ex vivo
stimulation assays.
In vitro IFN-c bioassay
Spleens from BALB/c mice were mechanically homogenized
and erythrocytes were lysed using ACK lysis buffer. Cells were
plated in 24-well plates at 2610
6 cells/ml in RPMI (Wisent)
supplemented with 10% FBS (Wisent), 1 mM penicillin-strepto-
mycin and 0.5 mM b-ME. Cells were stimulated with 100, 50, or
25 pg/ml of rIL-12 (R&D systems) or with concentrated bacterial
supernatants (L. lactis/secIL-12, L. lactis/vector). The supernatant
from L. lactis/secIL-12 was adjusted to provide ,50 pg/ml of IL-
12 per sample as determined by ELISA. Cells were co-stimulated
with anti-CD3 and anti-CD28 (0.5 mg/ml, 2.5 mg/ml, provided by
Dr. Fournier, McGill University). Anti-mIL-12 neutralizing
antibody (1 mg/ml, R&D Systems) was added to some samples
as indicated. Cells were incubated at 37uC under 5% CO2 for
24 hours and IFN-c concentration in the supernatant was
determined by ELISA (eBioscience).
Preparation of live bacteria for immunization
Saturated overnight cultures of L. lactis were diluted (,1/20) in
fresh media with antibiotics and grown until OD600=0.4–0.5.
Protein expression was induced with the addition of nisin to a final
concentration of 10 ng/ml and was grown for an additional
3 hours. L. lactis cells were collected by centrifugation, washed
twice in PBS, and resuspended in PBS+25% glycerol at 1/25th of
the starting culture volume. Aliquots of induced bacteria were
stored at 280uC. Prior to immunization, frozen aliquots were
thawed on ice, cells were spun down at 3,000 g at 4uC for 10 min
and resuspended in sterile PBS to obtain the desired concentra-
tion. Serial dilutions and colony forming units (CFU) counts were
performed on each batch of nisin-induced bacteria to determine
the dilution required to obtain ,10
10 CFU/ml. For each batch of
live L. lactis inocula prepared, protein expression was confirmed by
immunoblotting. Amounts of expressed protein per inoculum
(200 ml of bacteria) were determined by Western blot of whole cell
Table 1. Bacterial strains and primers used.
Strain name Description Source
L. lactis/vector NZ9000/pLE1 Mills et al. [36]
L. lactis/cytoLACK NZ9000/pDL-PnisA-LACK This study
L. lactis/secLACK NZ9000/pDL-PnisA-sec-LACK This study
L. lactis/cwaLACK NZ9000/pDL-PnisA-sec-LACK-cwa This study
L. lactis/secIL-12 NZ9000/pLE1-PnisA-sec-scIL-12opt This study
L. lactis/secIL-12 wt NZ9000/pSEC-PnisA-sec-scIL-12 wt Bermu ´dez-Humara ´n et al. [35]
Primer-pair name Description Sequence (F, forward; R, reverse)
LACKpDL PCR-amplify LACK gene for cloning into
pDL278
F: 59-CCA ATG CAT AAC TAC GAG GGT CAC CTG AAG-39
R: 59-CCA ATG CAT TTA CTC GGC GTC GGA GAT GG-39
Sec signal PCR-amplify Usp45 secretion signal F: 59-CCA ATG CAT AAA AAA AAG ATT ATC TCA GCT AT-39
R: 59-CCA ATG CAT ATC TGA GTT TGT GTC AGC G-39
LACK39NheI PCR-amplify a fragment containing the nisin
promoter, secretion signal and LACK gene to
add 39 NheI site (cloning site for cwa domain)
F: 59-CCG GAA TTC AGT CGA CCT AGT CTT ATA ACT ATA CTG ACA
ATA G-39
R: 59-AGC TGG CTA GCT CGG CGT CG GAGA TGG ACC A-39
CWA PCR-amplify cell-wall anchoring domain from
M6 protein of Streptococcus pyogenes
F: 59-CCA ATG CAT CGC TAG CTT TAG AAG AAG CAA ACA-39
R: 59-TGA GTG CTA GCT TAG TTT TCT TCT TTG CG-39
LACKpET PCR-amplify LACK gene for cloning into
pET-16b
F: 59-GGG AAT TCC ATA TGA ACT ACG AGG GTC ACC TG-39
R: 59-CGC GGA TCC TTA CTC GGC GTC GGA GAT GG-39
IL-12 PnisA PCR-amplify PnisA promoter for cloning into
pBS-scIL-12opt
F: 59-CAC CAG TAC TAG TCG ACC TAG TCT TAT AAC TAT ACT GAC AAT
AGA AAC ATT-39
R: 59-TGC GGA ATT CAT GCA TTT TGA GTG CCT CCT TAT AAT TTA T-39
doi:10.1371/journal.pone.0030945.t001
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the ‘‘Volume Analysis’’ function from the QuantityOne software
(Bio-Rad) using hisLACK (400 ng) or hisIL-12 (100 ng) purified
from E. coli as standards.
Mouse strains
Six to eight week old BALB/c mice were purchased from
Charles River Laboratories (Montreal, QC) and maintained in the
Duff Medical building animal facility under pathogen-free
conditions. All experiments were performed in accordance with
guidelines of the Canadian Council on Animal Care, as approved
by the Animal Care Committee of McGill University.
Immunization protocol
LACK and IL-12-expressing L. lactis were prepared as
described above. Groups of mice were subcutaneously immu-
nized in the back every second week for a total of three
immunizations (day 0, day 14, day 28). Mice were immunized
with 0.5610
9 live bacteria of one of the three strains expressing
LACK in combination with 0.5610
9 of live L. lactis expressing
either secIL-12 or carrying the empty vector (total dose of 1610
9
live bacteria). As controls, we immunized mice with PBS only,
with 1610
9 of live L. lactis/vector, or with 0.5610
9 live L. lactis/
secIL-12 in combination with 0.5610
9 live L. lactis/vector. All
immunizations were performed in a total volume of 200 ml. Mice
were challenged with Leishmania major Friedlin V9 infection on
day 42.
Parasite challenge and SLA preparation
Leishmania major Friedlin V9 was maintained at 25uCi n
SDM medium supplemented with 10% FBS (Wisent) as
previously described [38]. Mice were challenged with 5610
6
late-stationary phase L. major promastigotes in 50 mlP B Si n -
jected subcutaneously into the right hind footpad two weeks
following the last immunization (day 42). Disease progression
was monitored at weekly intervals, by measuring the thick-
ness of the infected footpad using a digital vernier calliper
and subtracting the thickness of the contralateral uninfected
footpad.
Footpad parasite burdens were determined by limiting
dilution as previously described [29]. The parasite burden of
each footpad was determined from the highest dilution in which
viable promastigotes could be grown after 7 days of culture at
25uC in SDM. For some experiments, footpad parasite burdens
were determined by PCR-ELISA as previously described [39].
In brief, tissue from infected footpads was homogenized and
DNA was isolated using TRIzol reagent (Invitrogen, Carlsbad,
CA). DNA concentrations were determined using NanoDrop
(Thermo Scientific) and samples were diluted to a final
concentration of 10 ng/ml. Parasite DNA for PCR standards
was prepared using the proteinase procedure [39]. PCR was
p e r f o r m e du s i n gd i g o x i g e n i n - l a b e l l e df o r w a r da n db i o t i n -
labelled reverse primers specific for kinetoplast minicircle DNA
[39]. Cycling conditions for PCR were as follows; 1 cycle at 94uC
for 90 s, followed by 20 cycles of 94uC for 30 s, 53uC for 45 s,
72uC for 60 s and a final extension for 10 min at 72uCu s i n ga
TGradient thermocycler (Biometra, Go ¨ttingen, Germany).
ELISA was performed as previously described, except that
plates were blocked after coating with PBS+5% FBS for 30 min
[39].
To prepare soluble Leishmania antigen (SLA), late-stationary
phase L. major promastigotes were resuspended in sterile
PBS to a concentration of ,10
8 parasites/ml. Parasites were
lysed by five cycles of freeze-thawing, then centrifuged at 4uC
for 15 min. The supernatant (SLA) was collected and protein
concentration was determined by Bradford assay (BioRad).
Serum antibody analysis
To determine end-point titers of LACK-specific antibodies,
blood was collected from immunized animals from the lateral
saphenous vein on day 35, four and ten weeks after parasite
challenge. Serum samples were stored at 280uC until analysis.
ELISA plates were coated with purified LACK protein (2.5 mg/
ml; 50 ml/well) at 4uCo v e r n i g h t .B e f o r ea n da f t e re v e r y
subsequent step, wells were washed with PBS+0.5% Tween-20
(PBS-T). Wells were blocked with PBS+2.5% FBS for 1 hour.
Two-fold serial dilutions of serum samples were prepared on
the ELISA plate at a starting dilution of 1/50 in PBS-FBS and
incubated for 2 hours at room temperature. Wells were then
incubated with secondary anti-mouse total IgG-HRP antibodies
(Sigma) and ABTS ELISA substrate (Sigma), and finally, plates
were read at 405 nm in a microplate reader (Bio-Tek; Winooski,
VT). The end-point was determined as the highest serum dilution
to reach at least the same absorbance reading as the average
plus two standard deviations of naı ¨ve pre-immune sera (1:50
dilutions).
To determine the levels of LACK-specific IgG1 and IgG2a
antibodies, two-fold serial dilutions of individual serum samples
were added on ELISA plates coated as above with purified LACK
protein. Then, goat anti-mouse IgG1 or IgG2a antibodies (Sigma)
and anti-goat-HRP antibodies (Sigma) were used to detect the
isotype of LACK-specific antibodies in sera. Reciprocal end-point
titers of LACK specific IgG1 and IgG2a antibodies were de-
termined as with total IgG antibodies.
Multiparameter flow cytometry
Spleens were collected from immunized animals two weeks
after the last immunization (day 42). Single-cell suspensions were
prepared in RPMI (Wisent) supplemented with 10% FBS
(Wisent), 1 mM penicillin-streptomycin and 0.5 mM b-ME and
1610
6 splenocytes were plated in 96-well plates in a total of
100 ml. Cells were stimulated with purified LACK (20 mg/ml)
and anti-CD28 (2 mg/ml) at 37uC for 2 hours. Brefeldin A
(10 mg/ml, Sigma-Aldrich) was added and cells were incubated
for 12 hours. Intra- and extracellular staining were performed
according to IC staining protocol by eBioscience. In brief, FccR
was blocked and cells were stained for CD3 (Pe-Cy7), CD4
(FITC) and CD8 (PerCP-Cy5.5). Cells were permeabilized using
Fixation/Permeabilization Buffer for 30 min and stained for IFN-
c (eFluor450), IL-2 (PE) and TNF-a (APC). Antibodies and
reagents for intracellular staining were purchased from
eBioscience. Samples were analyzed for intracellular cytokines
using CyAn ADP flow cytometer (Beckman Coulter, Mississauga,
ON) and data was analyzed using FlowJo software (Tree Star,
Ashland, OR).
Ex vivo stimulation of splenocytes and lymphocytes
Spleens or draining lymph nodes (popliteal and inguinal) were
collected from immunized animals two weeks after the last
immunization (day 42), 8 days after challenge (day 50) or at the
end of the infection timeline. Single-cell suspensions were prepared
in RPMI (Wisent) supplemented with 10% FBS (Wisent), 1 mM
penicillin-streptomycin and 0.5 mM b-ME and 2610
6 cells were
plated in 24-well plates in a total of 2 ml. Cells were stimulated
with purified LACK (10 mg/ml) or soluble Leishmania antigen
(SLA, 50 mg/ml) at 37uC under 5% CO2 for 3 days. Culture
supernatants were collected and stored at 280uC until cytokine
concentrations were quantified by ELISA. The concentration of
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Cytokine kits (eBiosicence) according to the manufacturer’s
protocol.
Statistical analysis
Statistical significance between two groups was determined
using the student T-test function of the StatView program, version
5.0 (SAS Institute Inc.; Cary, NC). P,0.05 was considered
statistically significant.
Results
Expression of the Leishmania major LACK protein and
biologically active mouse single chain IL-12 by
Lactococcus lactis
To generate an effective live vaccine against L. major,w e
generated strains of L. lactis expressing the protective LACK
antigen in three subcellular locations and a strain secreting mouse
single chain IL-12 as adjuvant. In brief, we generated a strain of L.
lactis expressing the LACK gene from L. major under the control of
the nisin inducible promoter, leading to the expression of LACK
in the cytoplasm (L. lactis/cytoLACK). To direct LACK expression
outside of bacterial cells, we added the Usp45 secretion signal to its
N-terminus (L. lactis/secLACK) [33,34]. To attach LACK at the
cell surface of L. lactis, the cell-wall anchoring domain of the M6
protein from Streptococcus pyogenes was added at the C-terminus of
the secLACK construct (L. lactis/cwaLACK) [34]. Similarly to L.
lactis/secLACK, a strain of L. lactis engineered to secrete mouse
single chain IL-12 was generated (L. lactis/secIL-12). It was
previously shown that the fusion of the two IL-12 subunits (p35–
p40), creating single chain IL-12 (p70), increased the production of
functional IL-12 when secreted from L. lactis [35].
Expression of LACK and IL-12 was confirmed by Western blot
and ELISA. After inducing protein expression with nisin, total cell
extracts and culture supernatants of LACK-expressing L. lactis
strains were resolved on SDS-PAGE and blotted using LACK-
specific antibodies (Fig. 1A). As expected, for L. lactis/cytoLACK
we detected LACK only in the cell extract. For L. lactis/secLACK
we were able to detect LACK in the bacterial supernatant as well
as in the cell extract. The secLACK protein detected in the
cytoplasm is larger than cytoLACK because it contains the
secretion signal, which is cleaved during secretion. Finally, for L.
lactis/cwaLACK we detected the LACK protein in both fractions.
Since cwaLACK contains both the secretion signal and the cell
wall anchoring domain, its size is larger than both cytoLACK and
secLACK. The smaller bands detected in the culture supernatant
possibly correspond to fragments of the LACK protein that were
shed during renewal of the cell-wall. We further confirmed protein
localisation by whole cell ELISA on live cells (Fig. 1B). Higher
expression of LACK was detected at the cell surface of L. lactis/
cytoLACK compared to background (L. lactis/vector), and it was
not detected in the culture supernatant. As expected, LACK was
detected at high levels on the cell surface and in the culture
supernatant for L. lactis/secLACK whereas LACK expressed from
L. lactis/cwaLACK was mainly detected at the cell surface.
Detection of cwaLACK at the surface of intact cells demonstrates
that the antigen protrudes sufficiently from the bacterial cell wall
to be recognized by antibodies. The Western blot and whole cell
ELISA results are coherent and confirm expression of the LACK
antigen by L. lactis in different subcellular locations.
We also confirmed protein expression from L. lactis/secIL-12
after nisin induction. Whole cell protein extracts of L. lactis/vector
and L. lactis/secIL-12 were resolved on SDS-PAGE and blotted
using mouse IL-12-specific antibodies (Fig. 1C). Single chain
mouse IL-12 was detectable from L. lactis/secIL-12 at approxi-
mately 70 kDa. To confirm protein secretion, we determined the
concentration of secreted IL-12p70 in concentrated L. lactis culture
supernatants by ELISA (Fig. 1D). To test if codon-optimization of
the mouse single chain IL-12 gene led to an increase in protein
production, we compared IL-12 concentration in supernatant
from L. lactis strains carrying either the wild type (L. lactis/secIL-
12 wt) [35] or the codon-optimized single chain mouse IL-12. In
order to prevent degradation of IL-12 during secretion, L. lactis
was grown in G3xM17. This medium possesses higher buffering
capacity and suppresses the acid tolerance response of L. lactis,
which leads to higher protein secretion [40]. We were able to
detect secretion of mouse IL-12 by both strains. However, bacteria
expressing the codon-optimized gene secreted approximately six
times higher amounts of IL-12 giving a geometric mean of
1.886 ng/ml in codon-optimized compared to 0.316 ng/ml in
wild-type. To determine whether the single chain IL-12 secreted
by L. lactis was biologically active, splenocytes from BALB/c mice
were stimulated with anti-CD3/anti-CD28 and concentrated
supernatant from L. lactis/secIL-12 to assess its ability to stimulate
IFN-c production (Fig. 1E). Concentrated bacterial supernatant of
the L. lactis strain expressing codon optimized single chain IL-12
was able to stimulate splenocytes to comparable levels as
recombinant IL-12 (25 pg/ml). In both cases, addition of an
anti-mouse IL-12 neutralizing antibody reduced IFN-c secretion
by splenocytes to background levels. These results confirm that
mouse single chain IL-12 secreted by L. lactis is able to stimulate
mouse splenocytes and hence is biologically active.
Subcutaneous vaccination with cwaLACK- and IL-12-
expressing L. lactis strains induces a significant delay in
footpad swelling in L. major infected BALB/c mice
The capacity of LACK- and IL-12-expressing L. lactis to protect
mice against cutaneous L. major challenge was evaluated. BALB/c
mice were subcutaneously immunized with one of the three
LACK-expressing L. lactis strains in combination with L. lactis
expressing secIL-12 or carrying the empty vector (total dose of
1610
9 live bacteria). As controls, mice were immunized with
either PBS, L. lactis/vector or L. lactis/secIL-12 in combination
with L. lactis/vector. Quantities of expressed proteins delivered per
immunization were estimated by Western blot (L. lactis/cyto-
LACK: ,14.860.9 mg, L. lactis/secLACK: ,12.661.4 mg, L.
lactis/cwaLACK: ,8.760.7 mg, L. lactis/secIL-12: ,5.360.1 mg).
Mice were immunized every second week for a total of three
immunizations. Two weeks after the final immunization, mice
were challenged with 5610
6 stationary L. major promastigotes
injected into the right hind footpad. Disease progression was
monitored by measuring footpad swelling every week (Fig. 2A).
Mice immunized with L. lactis/vector, L. lactis/secIL-12 or L.
lactis/cwaLACK displayed a similar increase in footpad swelling as
mice treated with PBS. However, animals immunized with L. lactis
expressing cwaLACK in combination with L. lactis secreting IL-12
displayed a significant delay in footpad swelling compared to the
groups immunized with PBS or L. lactis/vector, starting at four
weeks post-infection. In contrast, animals immunized with L.
lactis/cytoLACK or L. lactis/secLACK did not show reduced
footpad swelling, when administered alone or in combination with
L. lactis/secIL-12 (data not shown). The delay in footpad swelling
in animals immunized with L. lactis/cwaLACK in combination
with L. lactis/secIL-12 was associated with a significantly lower
parasite burden in the footpad compared to controls as determined
by PCR-ELISA and limiting dilution assay (Fig. 2B, 2C). Taken
together, these findings demonstrate that mice immunized with L.
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against L. major challenge.
Immunization with cwaLACK-expressing L. lactis induces
antigen-specific humoral immune responses
To characterize the immune response induced by the live
vaccine, we analyzed antigen-specific humoral responses before
parasite challenge (day 35, Fig. 3A) as well as at four (Fig. 3B) and
ten weeks (Fig. 3C) after challenge. Animals immunized with L.
lactis/cwaLACK and L. lactis/secIL-12 displayed mainly a TH2
humoral immune response against LACK characterized by
antigen-specific IgG1 titers. Additionally, LACK-specific IgG2a
antibodies were detected in these animals before and after
challenge, indicating the induction of a weak TH1 immune
response. In contrast, animals immunized with only L. lactis/
cwaLACK, showed LACK-specific IgG1 titers but antigen-specific
IgG2a titers were not detectable, indicating an antigen-specific
TH2 response. Generally, LACK-specific IgG1 and IgG2a
antibody titers in immunized animals were low, suggesting that
the live vaccine induced weak humoral immune responses.
Induction of antigen-specific multifunctional TH1 cells
correlates with protection against L. major infection
To evaluate the cellular immune responses induced by the live
vaccine, we assessed cytokine secretion in response to LACK
antigen by splenocytes from immunized animals. Mice were
immunized as described above and sacrificed two weeks after the
last immunization. Splenocytes of animals immunized with L.
lactis/cwaLACK and L. lactis/secIL-12 secreted significantly
higher amounts of IFN-c upon antigen restimulation compared
Figure 1. Expression and localization of the Leishmania LACK antigen and single-chain mouse IL-12 in L. lactis. (A) Western blot of total
protein extracts of LACK-expressing strains of L. lactis. T, total cell extract; S, culture supernatant. (B) Localization of expressed LACK was confirmed by
whole cell ELISA using anti-LACK antibody. C, intact cells; S, culture supernatant. * P,0.05 by unpaired T-test to L. lactis/vector. Data shown are
representative of three independent experiments with similar results. (C) Total protein extracts of L. lactis were analyzed for IL-12 expression by
Western blot using anti-IL-12p70 antibody. (D) Secretion of IL-12 by L. lactis was quantified using mouse IL-12p70 ELISA. * P,0.05 by unpaired T-test
to L. lactis/secIL-12 wt. Data shown are representative of at least three independent experiments with similar results. (E) IFN-c secretion by BALB/c
splenocytes stimulated with aCD3/aCD28 in combination with rIL-12 or concentrated supernatant from L. lactis secreting IL-12 was determined by
ELISA. * P,0.05 by unpaired T-test to aCD3/aCD28. Data shown are representative of three independent experiments with similar results.
doi:10.1371/journal.pone.0030945.g001
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Since the ratio of IFN-c to IL-10 is a correlate of immune
protection against L. major [41,42], we also quantified IL-10
secretion by restimulated splenocytes. Animals immunized with
L. lactis/cwaLACK and L. lactis/secIL-12 displayed a significant
increase in the IFN-c/IL-10 ratio compared to both PBS and
L. lactis/vector control groups (Fig. 4A, 4B). In addition,
restimulated splenocytes from animals immunized with L. lactis/
cwaLACK or L. lactis/cwaLACK and L. lactis/secIL-12 secreted
significantly higher amounts of IL-2 upon antigen recall,
compared to animals immunized with PBS (Fig. 4C). Secre-
tion of the TH2 cytokine, IL-4, was not detectable from
splenocytes of any of the groups after LACK restimulation (data
not shown).
To further characterize the cell-mediated immune responses
induced by the live vaccine, we determined TH1 cytokine
production by splenic CD4
+ and CD8
+ T cells using multiparam-
eter flow cytometry. Splenocytes of immunized mice were
cultivated in vitro with or without LACK and stained for CD3,
CD4, CD8, IFN-c, TNF-a, and IL-2 expression. Cells were gated
on live CD3
+, separated into CD4
+ and CD8
+ cells, and divided in
seven distinct populations of cytokine-producing cells. The quality
of the TH1 immune response induced by a vaccine is based on the
frequency of these distinct populations and there is evidence that
multifunctional TH1 cells are mediators of protection against L.
major challenge [41]. Significantly higher numbers of IFN-c
secreting CD4
+ T cells were found in restimulated splenocytes
from animals immunized with L. lactis/cwaLACK or L. lactis/
cwaLACK and L. lactis/secIL-12 compared to control groups
(Fig. 4D). Furthermore, immunization with the same L. lactis
strains induced multifunctional, antigen-specific CD4
+ T cells.
Higher frequency of CD4
+ T cells secreting IFN-c and IL-2, and
CD4
+ T cells producing IFN-c and TNF-a were detected in
splenocytes from these groups upon antigen recall (Fig. 4E).
Immunization with L. lactis/cwaLACK and L. lactis/secIL-12
induced significantly higher numbers of IFN-c
+ CD8
+ T cells. The
Figure 3. Antigen-specific humoral immune response following
immunization with LACK-expressing L. lactis. Mice were immu-
nized three times subcutaneously with PBS or different strains of L.
lactis and blood was collected one week after the last immunization (A),
four weeks after challenge (B) or ten weeks after challenge (C). LACK-
specific IgG1 and IgG2a antibody titers in sera were determined by
ELISA. Mean and SEM of four to five mice per group are shown.
* P,0.05 by unpaired T-test to PBS and L. lactis/vector. Data shown are
representative of two independent experiments with similar results.
doi:10.1371/journal.pone.0030945.g003
Figure 2. Immunization with L. lactis/cwaLACK and L. lactis/
secIL-12 delays footpad swelling and reduces parasite burden
in L. major infected BALB/c mice. Mice were immunized three times
subcutaneously with PBS or different strains of L. lactis and challenged
with L. major promastigotes into the right hind footpad. (A) Change in
footpad swelling post-infection was determined by measuring the
thickness of the infected footpad and subtracting the thickness of the
contralateral, uninfected footpad at weekly intervals. Animals were
sacrificed ten weeks after parasite challenge and parasite burden in
infected footpads was determined by (B) PCR-ELISA or (C) limiting
dilution. Mean and SEM of four to five mice per group are shown.
* P,0.05; ** P,0.01 by unpaired T-test to PBS and L. lactis/vector.
m P,0.05 by unpaired T-test to PBS. Data shown are representative of
three (A), one (B), or two (C) independent experiments with similar
results.
doi:10.1371/journal.pone.0030945.g002
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TH1 cells pre-challenge. Mice were immunized three times subcutaneously with PBS or different strains of L. lactis. Mice were sacrificed two weeks
after the last immunization and splenocytes were restimulated with purified LACK antigen ex vivo. (A, B) IFN-c, IL-10, and (C) IL-2 secretion after three
days of restimulation was determined by ELISA. (D) Splenocytes were restimulated for 16 hours and cytokine expression was analyzed by flow
cytometry. Frequencies of CD4
+ and CD8
+ T cells positive for IFN-c, IL-2, or TNF-a or the combination of the different cytokines are shown. (E) Fraction
of the total CD4
+ or CD8
+ response comprising cells expressing any two cytokines (2+), or any one cytokine (1+). Mean and SEM of four to five mice
per group are shown. * P,0.05; ** P,0.01 by unpaired T-test to PBS and L. lactis/vector.
m P,0.05 by unpaired T-test to PBS. Data shown are
representative of two independent experiments with similar results.
doi:10.1371/journal.pone.0030945.g004
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+, IFN-c
+ and IL-2
+ and mul-
tifunctional CD8
+, IFN-c
+, TNF-a
+ T cells, was also increased but
not significantly compared to controls.
Taken together, these results suggest that protection against L.
major infection in animals immunized with L. lactis/cwaLACK and
L. lactis/secIL-12 correlates with a systemic antigen-specific TH1
immune response and the induction of LACK-specific mono- and
multifunctional TH1 cells before challenge.
Protection against L. major infection correlates with
Leishmania-specific TH1 immune response after parasite
challenge
To examine the nature of protection against L. major induced by
L. lactis/cwaLACK and L. lactis/secIL-12, cytokine responses in
lymph node cells and splenocytes of immunized animals were
analyzed eight days and ten weeks after parasite challenge (Fig. 5).
Draining lymph nodes were collected and restimulated with
soluble Leishmania antigen (SLA) and cytokine secretion was
quantified (Fig. 5A–E). We first determined the ratio of IFN-c to
IL-10 secretion by restimulated lymphocytes at day 8 and found
that only animals immunized with L. lactis/cwaLACK and L.
lactis/secIL-12 displayed a significantly higher ratio compared to
animals immunized with PBS or L. lactis/vector (Fig. 5A, 5B). We
did not detect significant differences in IL-2 or IL-4 production
from restimulated lymph node cells among the groups (data not
shown). As expected, no antigen-specific cytokine secretion was
detected in restimulated splenocytes eight days after parasite
challenge (data not shown). At ten weeks post-challenge, the IFN-
c/IL-10 ratio was significantly higher in restimulated lymph node
cells from animals immunized with L. lactis/cwaLACK and L.
lactis/secIL-12 compared to controls (Fig. 5C, 5D). We also found
elevated IL-2 secretion by restimulated lymph node cells of
animals immunized with live bacteria but significantly higher
amounts in animals immunized with L. lactis/cwaLACK or L.
lactis/cwaLACK and L. lactis/secIL-12 compared to PBS (Fig. 5E).
IL-4 secretion by restimulated lymphocytes was detectable but no
statistically significant differences were found between the groups
(data not shown).
Similar results were obtained in SLA-restimulated splenocytes
in animals ten weeks after parasite challenge (Fig. 5F, 5G).
Animals immunized with L. lactis/cwaLACK and L. lactis/secIL-
12 displayed significantly higher secretion of IFN-c compared to
animals immunized with PBS and L. lactis/vector (Fig. 5F).
Figure 5. Protection against L. major infection correlates with Leishmania-specific TH1 response in immunized animals. Mice were
immunized three times subcutaneously with PBS or different strains of L. lactis and challenged with L. major. Mice were sacrificed eight days (A, B), or
ten weeks (C–G) after challenge (pm: post mortem). Lymph node cells (A–E), or splenocytes (F, G) were restimulated with SLA ex vivo. IFN-c, IL-10, and
IL-2 secretion by restimulated draining lymph node cells and splenocytes were determined by ELISA. Mean and SEM of four to five mice per group are
shown. * P,0.05; ** P,0.01 by unpaired T-test to PBS and L. lactis/vector.
m P,0.05 by unpaired T-test to PBS. Data shown are representative of two
independent experiments with similar results.
doi:10.1371/journal.pone.0030945.g005
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10 secretion by splenocytes of animals immunized with L. lactis/
cwaLACK and L. lactis/secIL-12 was not detectable (Fig. 5F).
Furthermore, IL-2 secretion by SLA-restimulated splenocytes
from animals immunized with L. lactis/cwaLACK and L. lactis/
secIL-12 was significantly higher compared to all other groups
(Fig. 5G). IL-4 secretion was not detectable in any of the groups
(data not shown).
In summary, these results indicate that animals immunized with
L. lactis/cwaLACK and L. lactis/secIL-12 display a strong anti-
Leishmania TH1 immune response detectable in draining lymph
nodes shortly after parasite infection as well as locally and
systemically at 10 weeks post-challenge.
Discussion
Leishmaniasis presently affects over 12 million individuals
worldwide and approximately 2 million new cases occur every
year. Current treatments are labour-intensive, expensive, cause
severe side effects and emerging drug resistance has been reported
[1,2]. Hence, further interventions against the disease are needed.
Vaccination is the most cost-effective means to control infectious
disease. Since leishmaniasis is mainly a disease of the developing
world, a vaccine against Leishmania has to be affordable to the
population in need, preferably stable at room temperature and
easy to administer, as well as safe and effective. The use of L. lactis
as a live vaccine shows promising results against various diseases
and has recently been shown to be safe for oral administration in
humans [26]. Furthermore, a live vaccine using strains of L. lactis
would be inexpensive to produce, stored simply as lyophilised
pellets and could be easily administered via mucosal routes. As a
first step towards the generation of L. lactis live vaccine against
Leishmania, we report effective subcutaneous immunization against
L. major infection in the mouse model.
We generated strains of L. lactis expressing the protective
Leishmania antigen LACK in three different subcellular locations
and a strain of L. lactis secreting biologically active mouse IL-12.
We demonstrated that L. lactis expressing codon-optimized IL-12
secretes approximately six times more IL-12 than the previously
described strain expressing the murine wild-type gene [35].
Subcutaneous immunization using these strains was well tolerated
by animals. Formation of skin ulcerations was occasionally
detected at sites of injection, however they resolved during the
following weeks. Only immunization with L. lactis/cwaLACK in
combination with L. lactis/secIL-12 conferred a delay in footpad
swelling and significant reduction in parasite burden in L. major
infected BALB/c mice. It is well established that the immunoge-
nicity of an antigen expressed by L. lactis depends on its subcellular
location [24]. However, it is difficult to predict the most
immunogenic expression strategy, since this depends on both the
antigen expressed and on the route of immunization. Our result
showing that only LACK anchored to the bacterial cell-wall was
able to induce a protective immune response against L. major
challenge is in accordance with the finding of Norton et al. [43].
They showed that subcutaneous immunization with L. lactis
expressing tetanus toxin fragment C (TTFC) anchored to the cell-
wall was more immunogenic than immunization with bacteria
expressing the antigen in the cytoplasm or secreted, and was able
to provide better protection against lethal challenge. Additionally,
our group previously showed that subcutaneous immunization
with L. lactis expressing A2 anchored to the cell-wall induced the
highest level of antigen-specific antibody titers compared to other
expression strategies and reduced parasite burdens in L. donovani-
challenged animals [29]. Therefore, we hypothesized that for
subcutaneous immunization with L. lactis, the expression of the
antigen anchored to the cell-wall would be the most immunogenic.
We showed in this study that immunization with L. lactis/
cwaLACK alone failed to induce a protective immune response
against L. major challenge, indicating the necessity for co-
administration of L. lactis/secIL-12 as a TH1-inducing adjuvant.
This is similar to previous studies where recombinant LACK was
shown to induce protection against parasite challenge only if the
antigen was administered with TH1-inducing agents or as a DNA
vaccine (reviewed in [7]). This also holds true for immunization
using LACK-expressing strains of bacteria. Lange et al. reported
that intravenous immunization with Salmonella expressing LACK
did induce Leishmania-specific TH1 immune response in BALB/c
mice but did not provide protection against parasite challenge
[17]. However, they reported successful immunization against
L. major challenge by heterologous prime-boost immunization
using LACK DNA and LACK-expressing Salmonella enterica. Soussi
et al. showed that intravenous immunization using LACK-
expressing Listeria monocytogenes failed to provide protection against
L. major challenge in BALB/c mice despite the induction of a
LACK-specific TH1 immune response [15]. However, the same
group reported partial protection against L. major infection if
animals were immunized intraperitoneally or intragastrically with
LACK-expressing Listeria [16]. With our L. lactis live vaccine, we
obtained protection comparable to the Salmonella prime-boost
strategy but better protection compared to immunization using
Listeria. However, the use of attenuated pathogenic bacteria as live
vaccine raises safety concerns, which is not an issue when using a
non-pathogenic and food grade bacterium such as L. lactis.
Another purpose of this study was to determine the mechanisms
of action of our L. lactis live vaccine. We first assessed the humoral
immune response induced after immunization. We found that
immunization with L. lactis/cwaLACK induced LACK-specific
IgG1 antibodies, indicating an antigen-specific TH2 immune
response. However, in animals immunized with L. lactis/
cwaLACK and L. lactis/secIL-12, LACK-specific IgG2a was also
detectable in sera pre- and post-challenge, indicating the induction
of a mixed TH1/TH2 response. In general, antibody titers in
immunized animals were low, indicating a weak humoral
response. This is in contrast to the strong humoral responses
induced by subcutaneous immunization using L. lactis expressing
the Leishmania antigen A2 or expressing TTFC anchored to the
bacteria cell wall [29,43]. The differences in antibody titers could
be explained by lower expression of the LACK antigen, or
differences in the processing of the antigens by immune cells.
However, induction of Leishmania-specific IgG has been shown to
exacerbate disease in L. major-infected mice [44,45]. Thus, the
induction of a weak humoral immune response might contribute
to the protective efficacy of our vaccine against L. major challenge.
To further characterize the L. lactis live vaccine, we assessed the
cell-mediated immune response induced before and after L. major
challenge. Immunization with L. lactis/cwaLACK and L. lactis/
secIL-12 induced an antigen-specific TH1 response. Only animals
immunized with this combination of the L. lactis strains showed a
significant increase in the IFN-c/IL-10 ratio, which is an
important correlate of immune protection against L. major [42].
In addition, immunization with L. lactis/cwaLACK and L. lactis/
secIL-12 induced antigen-specific multifunctional TH1 cells.
Induction of these cells, which are capable of producing several
TH1 cytokines, was correlated with protection against L. major
infection [41]. Immunization using L. lactis/cwaLACK alone also
induced antigen specific CD4
+, IFN-c
+ T cells albeit at a lower
level. Similarly, fewer LACK-specific multifunctional CD4
+ and
CD8
+ cells expressing IFN-c and TNF-a were detected in these
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cwaLACK is able to induce IFN-c production and multifunctional
TH1 cells. However, the degree and/or the quality of the TH1
immune response induced by L. lactis/cwaLACK was not sufficient
to protect against L. major challenge and a protective immune
response was only achieved with the adjuvant effect of L. lactis/
secIL-12.
Protection against L. major infection correlated with a strong
Leishmania-specific TH1 immune response post-challenge in
immunized animals. This was detectable as early as eight days,
but also at ten weeks after challenge, in lymph nodes draining the
site of infection. Similarly, a strong systemic TH1 response was
detected at ten weeks after immunization, indicated by the high
levels of IFN-c and the absence of IL-10 in restimulated
splenocytes. Animals immunized with only L. lactis/cwaLACK
did not display a Leishmania-specific TH1 immune response,
indicating the need for L. lactis/secIL-12 as adjuvant to induce a
protective immune response against the parasite. These observa-
tions show that in our infection model, vaccine efficacy can be
predicted by the ratio of antigen-specific production of IFN-c to
IL-10 and that protected animals continue to display a Leishmania-
specific TH1 immune response. Furthermore, the ratio of IFN-c to
IL-10 was also an indicator of the protective immune response
post-challenge, which is in accordance to findings in other L. major
infection models [42,46].
In summary, we showed that the LACK antigen of Leishmania,
as well as mouse IL-12, can be effectively expressed by L. lactis.W e
further demonstrated that subcutaneous immunization with L.
lactis/cwaLACK and L. lactis/secIL-12 delayed footpad swelling
and significantly reduced parasite burden in L. major infected
BALB/c mice. Protection correlated with the induction of LACK-
specific multifunctional TH1 cells before challenge and Leishmania-
specific TH1 immune response after challenge. The L. lactis strains
generated provide the basis for the development of an inexpensive,
safe and effective Leishmania vaccine.
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